

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/204108 A1

(51) International Patent Classification:

C07J 71/00 (2006.01) A61P 19/02 (2006.01)
A61P 17/00 (2006.01)

(21) International Application Number:

PCT/US2022/021299

(22) International Filing Date:

22 March 2022 (22.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/164,613 23 March 2021 (23.03.2021) US
63/260,451 20 August 2021 (20.08.2021) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).


(72) Inventors: **AHMED, Adel Ahmed Rashad**; c/o ELI LILLY
AND COMPANY, P.O. Box 6288, Indianapolis, Indi-

ana 46206-6288 (US). **CLAYTON, Joshua Ryan**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In-
diana 46206-6288 (US). **LOPEZ, Jose Eduardo**; c/o ELI
LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In-
diana 46206-6288 (US). **MCMILLEN, William Thomas**;
c/o ELI LILLY AND COMPANY, P.O. Box 6288, In-
dianapolis, Indiana 46206-6288 (US). **STITES, Ryan**
Edward; c/o ELI LILLY AND COMPANY, P.O. Box
6288, Indianapolis, Indiana 46206-6288 (US). **WILSON,**
Takako; c/o ELI LILLY AND COMPANY, P.O. Box
6288, Indianapolis, Indiana 46206-6288 (US). **WURST,**
Jacqueline Mary; c/o ELI LILLY AND COMPANY, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US).



(74) Agent: **LENTZ, Nelsen L.** et al.; ELI LILLY AND COM-
PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: GLUCOCORTICOID RECEPTOR AGONISTS



Formula I



(57) Abstract: The present invention provides a compound of Formula I: wherein R is H or R¹ is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF₃, R² is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl; R³ is NH₂, or CH₂NH₂; and X is O, OCH₂, OCH₂CH₂, OCH(CH₃), CH₂O, SCH₂, CH₂S, CH₂, NHCH₂, CH₂NH, N(CH₃)CH₂, CH₂CH₂, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*